Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.47 |
| ▸ | BAD | Q92934 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.41 |
| ▸ | KCNN4 | O15554 | 3/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5202085 | 1.00 | CES2 (0.48) | CES2CES1BCL2L1BADCA1 | |
| SCHEMBL29089411 | 0.81 | MAPT (0.51) | MAPTNPC1RAB9APKMTNFRSF1A | |
| SCHEMBL29089415 | 0.81 | MAPT (0.51) | MAPTNPC1RAB9APKMTNFRSF1A | |
| SCHEMBL27701700 | 0.81 | MAPT (0.50) | CES2CA1CA2MAPTRAB9A | |
| SCHEMBL28337358 | 0.80 | TDP1 (0.54) | CES2CES1CA1CA2MAPT | |
| SCHEMBL4240914 | 0.80 | TDP1 (0.54) | CES2CES1CA1CA2MAPT | |
| SCHEMBL4240912 | 0.80 | TDP1 (0.54) | CES2CES1CA1CA2MAPT | |
| SCHEMBL6662812 | 0.79 | ALOX15 (0.52) | CES2CES1CA1CA2MAPT | |
| SCHEMBL6662810 | 0.79 | ALOX15 (0.52) | CES2CES1CA1CA2MAPT | |
| SCHEMBL3165945 | 0.78 | CES2 (0.52) | CES2CES1BCL2L1BADCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054924-A1 | Novel piperidines as chemokine modulators (ccr) | ASTRAZENECA AB (SE) | 2007-03-08 | — | — | US | disclosed |
| EP-1713772-A1 | NOVEL PIPERIDINES AS CHEMOKINE MODULATORS (CCR) | AstraZeneca AB (SE) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005073192-A1 | NOVEL PIPERIDINES AS CHEMOKINE MODULATORS (CCR) | ASTRAZENECA AB (SE) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054924-A1 | Novel piperidines as chemokine modulators (ccr) | CCR3, CCR1, CCR4 | CES2 878/4885CES1 924/4885BCL2L1 3720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.